Implementation of a stepwise process for somatic testing in patients with a new diagnosis of germline negative epithelial ovarian cancer
We successfully increased somatic testing recommendations in germline BRCA negative patients prior to completing upfront EOC treatment allowing for a timely, individualized discussion of maintenance PARP inhibitor use. Qualitative assessment of patients' comprehension of genetic testing for EOC shows a deficit in patient knowledge.
Authors
- Laura Ongie (ORCID: https://orcid.org/0000-0002-8354-1907)
- Vonda Wall
- Sanjna Rajput (ORCID: https://orcid.org/0000-0002-8305-421X)
- Myra Wick (ORCID: https://orcid.org/0000-0003-4126-4523)
- Clarissa Polen-De (ORCID: https://orcid.org/0000-0003-3079-7121)
- Karen Schaepe
- Amanika Kumar (ORCID: https://orcid.org/0000-0002-1470-1305)
- Sara Klennert
- Megan E. Grudem (ORCID: https://orcid.org/0009-0003-9533-3181)
- Kristin Cole (ORCID: https://orcid.org/0000-0001-5543-5341)
- Carolyn M. Klampe
- Casey Lawler
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1016/j.gore.2025.101935
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00